To clarify the role of MSCs in glioma progression, we classified glioma patients in The Cancer Genome Atlas (TCGA) into MSC-high and MSC-low groups based on coexpression of the MSC markers CD73, CD90 and CD105 (accessed via http://gepia2.cancer-pku.cn/). This evidence concerns the gene THY1 and central nervous system cancer.